Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS)

CNY 51.9

(0.31%)

Market Cap (In CNY)

11.4 Billion

Revenue (In CNY)

1.02 Billion

Net Income (In CNY)

162.93 Million

Avg. Volume

3.82 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
35.63-81.5
PE
-
EPS
-
Beta Value
0.557
ISIN
CNE1000051X5
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Wei Ding
Employee Count
-
Website
https://www.sinopep.com.cn
Ipo Date
2021-05-20
Details
Sinopep-Allsino Bio Pharmaceutical Co.,Ltd., a biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. The company offers formulations, such as thymalfasin products for injection, eptifibatide injections, alogliptin benzoate tablets, and oseltamivir phosphate capsules; APIs and intermediates; and drugs for type 2 diabetes and obesity, and coronavirus. It also provides pharmaceutical research, clinical, and registration services of drugs; and undertakes CDMO/CMO projects of small molecule chemical API and intermediates. The company was founded in 2009 and is headquartered in Hangzhou, China.